A Phase 2 randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of AL002 in patients with prodromal to mild Alzheimers disease
Study of AL002 for Patients with Early Alzheimers Disease
Sponsor: Alector Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT2514
U.S. Govt. ID: NCT04592874
Contact: Katrina Cuasay: 212-305-2077 / kc2305@cumc.columbia.edu
Additional Study Information: This is a phase 2 study evaluating a new drug, AL002, in persons with early Alzheimer's Disease. Participants will be randomized to receive either AL002 or placebo, intravenously every four weeks, for a total period of about two years. The purpose is to evaluate the efficacy and safety of this drug, and this study involves pen and paper testing, and MRI and PET scans.
This study is closed
Investigator
Lawrence Honig, MD, PhD
Do You Qualify?
Are you between the ages of 50-85? Yes No
Have you been diagnosed with Alzheimers disease? Yes No
Do you have an available study partner? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Katrina Cuasay
kc2305@cumc.columbia.edu
212-305-2077
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE